Evidence map›Paper›PMID 35892921›Full record

ArticleLife (Basel, Switzerland)2022

MGRN1 as a Phenotypic Determinant of Human Melanoma Cells and a Potential Biomarker.

Marta Abrisqueta, Sonia Cerdido, José Sánchez-Beltrán, Idoya Martínez-Vicente, Cecilia Herraiz, Ana Lambertos, Conchi Olivares, Arrate Sevilla, Santos Alonso, María Dolores Boyano and 2 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. AnInternational journal of molecular sciences · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Marta AbrisquetaDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.
Sonia CerdidoDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.
José Sánchez-BeltránDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.
Idoya Martínez-VicenteDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.
Cecilia HerraizDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.
Ana LambertosDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.ORCID 0000-0001-5616-2218
Conchi OlivaresDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.ORCID 0000-0001-7518-3858
Arrate SevillaDepartment of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, 48940 Leioa, Spain.
Santos AlonsoDepartment of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, UPV/EHU, University of Basque Country UPV/EHU, 48940 Leioa, Spain.
María Dolores BoyanoDepartment of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID 0000-0001-6051-1054
José Carlos García-BorrónDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.
Celia Jiménez-CervantesDepartment of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, LAIB Building, Room 1.53, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 Murcia, Spain.ORCID 0000-0002-5821-9510
Instituto Murciano de Investigación Biosanitaria · ESUniversity of the Basque Country · ESUniversidad de Murcia · ES

Funding

Ministry of Economy, Industry and Competitiveness SAF2018_RTI2018-094929-B-I00University of the Basque Country UPV/EHU GIU20/035
6 · The paper itself

Abstract

Mahogunin Ring Finger 1 (MGRN1), a ubiquitin ligase expressed in melanocytes, interacts with the α melanocyte-stimulating hormone receptor, a well-known melanoma susceptibility gene. Previous studies showed that MGRN1 modulates the phenotype of mouse melanocytes and melanoma cells, with effects on pigmentation, shape, and motility. Moreover, MGRN1 knockdown augmented the burden of DNA breaks in mouse cells, indicating that loss of MGRN1 promoted genomic instability. However, data concerning the roles of MGRN1 in human melanoma cells remain scarce. We analyzed MGRN1 knockdown in human melanoma cells. Transient MGRN1 depletion with siRNA or permanent knockdown in human melanoma cells by CRISPR/Cas9 caused an apparently MITF-independent switch to a more dendritic phenotype. Lack of MGRN1 also increased the fraction of human cells in the S phase of the cell cycle and the burden of DNA breaks but did not significantly impair proliferation. Moreover, in silico analysis of publicly available melanoma datasets and estimation of MGRN1 in a cohort of clinical specimens provided preliminary evidence that MGRN1 expression is higher in human melanomas than in normal skin or nevi and pointed to an inverse correlation of MGRN1 expression in human melanoma with patient survival, thus suggesting potential use of MGRN1 as a melanoma biomarker.

Indexed as

biomarkerDNA damageMahogunin Ring Finger 1 (MGRN1)melanocytesmelanoma

Identifiers

PMID35892921
PMCPMC9331370
OpenAlexW4288068844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.